

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



友芝友生物製藥

**WUHAN YZY BIOPHARMA CO., LTD.**

**武漢友芝友生物製藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 2496)**

## **INSIDE INFORMATION**

### **PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION BY THE COMPANY**

This announcement is made by Wuhan YZY Biopharma Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the Guidelines on Application for “Full Circulation” of Domestic Unlisted Shares of H-share Companies (《H股公司境內未上市股份申請“全流通”業務指引》) issued by the China Securities Regulatory Commission (the “**CSRC**”) on November 14, 2019 and further amended on August 10, 2023 (the “**Guidelines**”).

In view of the Guidelines, the board (the “**Board**”) of directors (the “**Directors**”) of the Company has considered and approved the proposed implementation of full circulation (the “**H Share Full Circulation**”) of 68,010,299 domestic shares and unlisted foreign shares of the Company, representing approximately 35.08% of the Company’s total issued capital as of the date of this announcement, held by certain shareholders of the Company (the “**Participating Shareholders**”). Upon obtaining all relevant approvals (including the filing notice by the CSRC) and having complied with all applicable laws, rules and regulations, such domestic shares and unlisted foreign shares will be converted into H shares of the Company (“**H Shares**”) and the Company will apply to The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) for the listing of, and permission to deal in, such H Shares on the Main Board of the Stock Exchange (the “**Conversion and Listing**”).

As of the date of this announcement, the Company has not submitted the filing application to the CSRC for the H Share Full Circulation. The Company will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in accordance with the Inside Information Provisions and/or the requirements of the Listing Rules.

**The H Share Full Circulation and the Conversion and Listing are subject to other relevant procedures as required by the CSRC, the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Wuhan YZY Biopharma Co., Ltd.**

**Dr. Zhou Pengfei**  
*Chairman of the Board, Executive Director and Chief  
Executive Officer*

Wuhan, PRC, May 12, 2025

*As at the date of this announcement, the Board comprises Dr. Zhou Pengfei as executive Director; Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu, Ms. Liang Qian, Mr. Wen Zhicheng and Mr. Xie Shouwu as non-executive Directors; and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive Directors.*